WINQ Eyelid Serum: The Clinically-Proven Solution for Digital Eye Strain
A Solution to Screen-Induced Dry Eye:
This unique serum targets the root cause of screen-induced discomfort by restoring the natural blink mechanism, directly supporting tear film health, and offering rapid relief in a single, dual-action product.
Targeting the Cause of Screen Fatigue
The WINQ Eyelid Serum is an innovative, evidence-based therapy. It uses gentle cooling plant extracts to target the TRPM8 cold receptors in the periocular area, which naturally activates and increases the patient’s subconscious blink rate. This action helps to constantly refresh the tear film, reduce evaporation, and alleviate eye fatigue.
Key Features of WINQ
Clinically Proven
A Randomised Controlled Trial (RCT) showed a significant 36% increase in blink rate and a 50% reduction in partial blink rate post-application.
Dual-Action Therapy
Combines essential eye health benefits (blink activation, hydration) with premium skincare ingredients, increasing patient appeal
Key Ingredients
Contains Hyaluronic Acid (HA) for superior hydration and lubrication, alongside Caffeine and Niacinamide to visibly reduce puffiness and dark circles.
Find out more about WINQ Eyelid Serum
Doctor Eye Health takes you throughthe key beenfits of WINQ.
Our Downloads
WINQ Clinical Study
PDF, 488KB
Interested in using WINQ Eyelid Serum in your practice?
Contact us to find out more about WINQ Eyelid Serum and to order.
References:
1. Mertzanis P, Venkataraman K, Begley C, Chalmers R, Abetz L. The Impact of Dry Eye on Daily Life: Results from a Qualitative Study. Investigative
Ophthalmology & Visual Science December 2002, Vol.43, 74.
2. Kitazawa M, Sakamoto C, Yoshimura M, Kawashima M, Inoue S, Mimura M, Tsubota K, Negishi K, Kishimoto T. The Relationship of Dry Eye Disease with
Depression and Anxiety: A Naturalistic Observational Study. Transl Vis Sci Technol. 2018 Dec 28;7(6):35. doi: 10.1167/tvst.7.6.35. PMID: 30619655; PMCID: PMC6314109.
3. Sarkar J, Chaudhary S, Namavari A, Ozturk O, Chang JH, Yco L, Sonawane S, Khanolkar V, Hallak J, Jain S. Corneal neurotoxicity due to topical benzalkonium chloride. Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1792-802. doi: 10.1167/iovs.11-8775. PMID: 22410563; PMCID: PMC3995561.
4. Sarkar J, Chaudhary S, Namavari A, Ozturk O, Chang JH, Yco L, Sonawane S, Khanolkar V, Hallak J, Jain S. Corneal neurotoxicity due to topical benzalkonium chloride. Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1792-802. doi: 10.1167/iovs.11-8775. PMID: 22410563; PMCID: PMC3995561.
Read the news on
Positive Impact
Positive Impact (PI) confirms that its exclusive partnership with CSI Innovations (CSI) formerly known as CSI Dry Eye Software, has ended under a revised UK distribution structure for the Canadian software brand.
The opticians’ favourite lens cleaning system is now more accessible than ever. We’ve removed the barrier of initial capital investment so you can focus on patient loyalty and practice growth.
Positive Impact (PI) will be showing its independent-only portfolio and launching two new diagnostic instruments.
This will be the debut for the return of the Keratron topographer range to the UK.